checkAd
    Startseite > Aktien > PMV Pharmaceuticals > Nachrichten
    PMV Pharmaceuticals Aktie
    1,8700
     
    USD
    +0,54 %
    +0,0100 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,8600
     
    USD
    2.800 STK
    Geldkurs 02.05.24
    1,8700
     
    USD
    2.600 STK
    Briefkurs 02.05.24
    ISIN: US69353Y1038 · WKN: A2QCB3 · SYM: PMVP · USA

    Neueste Nachrichten

    PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors
    27.03.24 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer
    18.03.24 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights
    29.02.24 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference
    26.02.24 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway
    18.01.24 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development
    05.01.24 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights
    09.11.23 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
    12.10.23 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
    11.10.23 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    20.09.23 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals Reports Second Quarter 2023 Financial Results and Corporate Highlights
    09.08.23 · globenewswire · PMV Pharmaceuticals
    PMV Pharmaceuticals to Participate in the Goldman Sachs Global Healthcare Conference
    06.06.23 · globenewswire · PMV Pharmaceuticals